Due Diligence on Infusion RCM Operations in PE Acquisitions

PE completed all disclosed infusion therapy deals in 2024, which is not a broad healthcare trend but a sector-specific consolidation wave. An investment bank presentation from August 2025 made the thesis explicit: the infusion therapy services industry is regionally fragmented, and that fragmentation is what makes it ripe for roll-ups and platform building.

PE firms buying infusion practices at scale

An Option Care Health analysis counts more than 800 privately-owned infusion companies operating in the U.S., most of them running without the kind of institutional-grade revenue cycle management infrastructure a buyer would expect at this deal size. That is a deep pool of targets, and most of these practices are not held to any standard playbook. Some, to close that gap, have turned to dedicated infusion billing platforms; Ruby RCM, a revenue cycle management platform built solely for infusion centers that handles everything from prior authorizations and claims through denials and AR, is one such option. Due diligence has to build the yardstick itself rather than borrow one.

The site-of-care trend adds momentum. Freestanding ambulatory infusion centers are on pace to pass hospital outpatient departments in infusion volume by 2029, and they carry a real cost advantage over hospital settings. The acquisition pool is wide open and mostly unaudited, and that is precisely why the revenue sitting on a target's books deserves more scrutiny than it usually gets before a letter of intent gets signed.

Unreliable Reported Revenue at Infusion Targets

Most of those 800-plus privately-owned infusion companies lack institutional-grade RCM infrastructure, and that has a direct consequence: reported net revenue is rarely reconciled against contracted payer rates or against the root causes behind denials.

Underpayments show the problem most clearly. Without line-level remittance reconciliation, that leakage is invisible on a standard financial statement, and it will not appear in the management accounts a seller hands over at LOI. The gap is structural.

Detection rates make the scale of this visible. The industry standard is that practices catch only roughly a third to half of the underpayments they actually encounter, while high-performing centers catch the large majority. That spread means two practices can report identical revenue and sit on wildly different amounts of real, collectible cash. Typical infusion centers lose an average of three to seven percent of net revenue to underpayments, while high performers hold that figure to one percent or less. Across a multi-site platform, that difference compounds fast, and it is money a buyer may be underwriting as if it already exists.

This is not a fringe problem limited to disorganized, undercapitalized practices. The Adonis survey of more than 120 RCM leaders across 18 specialties found that nearly two-thirds named denials and underpayment management as a top obstacle heading into 2026. Even sophisticated, well-run operators are losing ground here, which should tell any buyer that reported revenue at an infusion target needs independent reconciliation before it gets treated as fact.

The structural deterioration of the RCM environment acquirers are buying into

The payer environment infusion acquisitions are closing into in 2026 punishes weak RCM harder than at any earlier point in this consolidation wave. Buyers who underwrite a deal assuming payer behavior will hold steady from 2024 or 2025 are mispricing the operational risk sitting inside the target.

Experian Health's State of Claims 2025 found that the share of providers reporting denial rates above ten percent has grown substantially since 2022. That is not a plateau, it is a worsening trend, and it means the baseline denial exposure in any infusion target bought today is likely higher than it would have been just a few years ago. Audit activity is rising alongside it: MDaudit's benchmarking data shows risk-based audits climbing and pre-bill audits rising sharply through 2025. Infusion is high-cost care, and high-cost care draws disproportionate audit attention.

Payer adjudication rules are shifting underneath practices. The Adonis survey found that roughly half of RCM leaders pointed to frequent changes in payers' adjudication rules as a major factor limiting their ability to collect revenue in 2025. A target with a thin compliance posture is leaking revenue today while quietly accumulating recoupment exposure that transfers directly to whoever buys it.

Prior authorization as the first RCM metric to stress-test in an infusion acquisition

Prior authorization in infusion is a recurring obligation tied to the calendar, repeating at defined intervals across a patient's entire treatment course, and a target without a documented renewal calendar is carrying a revenue cliff hidden inside its own patient panel.

Some health insurers require prior authorization at set intervals throughout an infusion course, including step therapy requirements and periodic reauthorizations meant to confirm treatment is still working. Some Marketplace and Medicare Advantage plans require a brand-new approval every year, even for patients who have been stable on the same therapy for years. A missed renewal is not a single denied claim. It can halt an entire ongoing course of a high-dollar biologic mid-treatment.

The regulatory landscape makes this harder, not easier. CMS-0057-F now requires Medicare Advantage and certain other plans to provide electronic prior authorization for non-drug medical items and services, but no finalized rule yet covers Part B drugs or Part D pharmacy benefits. CMS's 2026 proposed rule, CMS-0062-P, would extend electronic prior authorization to both, which would include physician-administered infusion therapy in outpatient and home settings. Until that rule finalizes, infusion practices have no mandated electronic pathway for drug authorizations, and the entire burden rests on how disciplined the practice's own operations are.

The rule that did take effect adds pressure from the other direction. CMS-0057-F became operational on January 1, 2026, and it requires impacted payers to decide standard prior authorization requests within 7 calendar days and expedited requests within 72 hours. Faster payer decisions sound like a win for practices, but they also shrink the window a practice has to respond once a determination comes back adverse.

Staffing data shows how much this already costs. MGMA's Annual Regulatory Burden Report found that nearly all medical group practices have hired or reassigned staff specifically to manage growing prior authorization volume, and most report that at least three employees touch a single request before it's resolved. Major payers like UnitedHealthcare update their authorization requirements throughout the year, typically monthly, with extra changes added mid-cycle whenever a new drug or procedure launches. Someone has to actively watch for these changes as they happen.

For any buyer evaluating an infusion target, the authorization renewal calendar is the first thing to ask for, along with the tracking method used by payer and by drug, and the rate of authorization lapses over the prior 12 months. If the target can't produce a clear answer, that absence is a structural finding about how the business runs.

Buy-and-bill drug economics and billing errors as capital events

Infusion runs on a buy-and-bill model: the practice buys the drug and administers it to the patient before it ever gets reimbursed. The denial doesn't just cost future revenue, it creates an immediate working capital problem.

Centers have to purchase expensive specialty drugs well ahead of getting paid for them, sometimes weeks or months in advance, and average annual drug costs per infusion patient run from the tens of thousands of dollars into well over a hundred thousand. A single denied or delayed claim on a high-cost biologic can leave tens or even hundreds of thousands of dollars stuck in limbo, and at a multi-site platform treating a full patient census, that exposure multiplies quickly.

Reimbursement is tied to Average Sales Price, and when a drug's acquisition cost rises faster than its ASP reimbursement, the practice loses money on the drug itself, regardless of whether the claim gets paid at all.

J-code billing adds another layer of exposure. As of January 1, 2026, CMS rejects any claim submitted with a discontinued HCPCS code, and there's no grace period. Common error patterns in diligence include units billed according to vial packaging instead of the actual HCPCS descriptor definitions, which creates overbilling or underpayment, and incorrect sequencing of infusion CPT codes, where the primary infusion code only applies to the first substance administered and every additional drug in that same encounter needs its own code for sequential or concurrent infusion, each reimbursed differently.

The fix is to ask the target directly for its quarterly HCPCS code update process and a sample remittance reconciliation showing ASP against actual payment received, by J-code. A target that can't produce a documented ASP validation workflow is carrying systematic underpayment as a permanent, recurring cost.

What denial patterns in an infusion target reveal about its operations

A denial rate by itself is a symptom. The real underwriting signal is the root-cause distribution behind those denials, broken out by payer, by denial type, and by where in the workflow the error originated, and most targets simply cannot produce that breakdown.

HFMA's benchmarking work names errors in diagnosis coding, modifier usage, and insufficient medical record documentation as the three biggest drivers of coding-related denials. A dashboard can tell a buyer that denials rose last month. It can't say whether those denials started at intake, at documentation, during authorization, in coding, or in billing, and that distinction decides whether the fix is a process redesign or simple staff retraining.

HFMA's benchmark report classifies ninety percent of denials as avoidable. The large majority of denial volume at a typical target can be fixed, but only once the root cause gets correctly identified by stage and by payer. Payer-specific behavior matters just as much as the root cause: different payers apply different adjudication rules, different audit triggers, and different step therapy requirements, so a denial rate that looks fine in aggregate can still hide a badly broken relationship with one or two payers that dominate the target's local market.

General RCM reviews tend to miss the denial causes specific to infusion: authorization lapses between treatment cycles, ASP repricing applied by payers on J-codes, mismatches between concurrent and sequential infusion codes, and thin medical necessity documentation for biologics that carry step therapy requirements. A buyer should request a denial report segmented by payer, by denial reason code, and by point of origin in the workflow, covering the trailing year. If a target can only hand over an aggregate denial rate, that missing segmentation is itself the finding, not a gap to shrug off as a data limitation.

AR aging at infusion targets and the true collectability of the revenue base

Accounts receivable aging in infusion doesn't measure how long it takes to get paid. It measures how much of that revenue is at risk of never getting paid at all, and because high-dollar claims concentrate in the aging buckets, that distinction has a direct effect on enterprise value.

High-performing physician groups keep their days in AR in the mid-thirties, with the best operators coming in even lower. Practices struggling with their revenue cycle have days in AR well above that, and a large share of those balances sit in the bucket where payers start treating the claim as effectively non-collectible. In infusion, where a single claim can represent tens of thousands of dollars in drug cost alone, an aging claim is an impaired asset, and once it crosses the payer's timely-filing window, that impairment is usually permanent.

Collection rates fall off sharply once AR crosses that critical age threshold, and the root cause almost always traces back to a denial backlog, slow payer follow-up, or a missed authorization window. The first-pass acceptance rate tells the same story from a different angle: the industry standard runs between roughly three-quarters and four-fifths of claims accepted on first submission, while high performers hit ninety percent or better. That gap drives AR aging directly, and it shows a buyer how much rework the billing team is quietly absorbing behind the scenes.

Evaluating a target's AR means checking whether it's segmented by payer, by aging bucket, and by dollar threshold, and whether a high-dollar worklist exists so aging claims get reviewed promptly rather than left to drift. AR that isn't segmented this way is evidence the team isn't managing collections at the level of granularity the business actually requires. Treating that unsegmented AR balance as a clean asset on the purchase price means paying full value for receivables that may never convert to cash.

What the operating model of an infusion RCM team tells a buyer that financial statements cannot

Financial statements show outcomes. They don't show how those outcomes got produced, and in infusion, the operating model behind the numbers is where the real underwriting work has to happen. A practice can report acceptable revenue, an acceptable denial rate, and acceptable days in AR, and still be one payer policy change away from a collapse, if the team behind those numbers is running on manual tracking, informal escalation, and no documented process for catching errors before they become losses.

The operational questions are the ones worth asking, not the financial ones, and each points to a person, a process, or a gap, with the answer revealing whether the target's current revenue is a repeatable result or a number that happened to hold up this year.

A target that can answer all of these with documentation and process maps is underwriting its own revenue the way a buyer should want it underwritten. That is where the actual risk in an infusion acquisition lives, and it is where due diligence has to start.